Cargando…

Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19

The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted...

Descripción completa

Detalles Bibliográficos
Autores principales: Wongso, Hendris, Mahendra, Isa, Arnafia, Wyanda, Idar, Idar, Yusuf, Muhammad, Achmad, Arifudin, Holik, Holis A., Kurniawan, Ahmad, Halimah, Iim, Sriyani, Maula E., Wibawa, Teguh H. A., Febrian, Muhamad B., Setiadi, Yanuar, Widyasari, Eva M., Daruwati, Isti, Kusumaningrum, Crhisterra E., Subroto, Toto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778912/
https://www.ncbi.nlm.nih.gov/pubmed/35062789
http://dx.doi.org/10.3390/vaccines10010128
_version_ 1784637445240782848
author Wongso, Hendris
Mahendra, Isa
Arnafia, Wyanda
Idar, Idar
Yusuf, Muhammad
Achmad, Arifudin
Holik, Holis A.
Kurniawan, Ahmad
Halimah, Iim
Sriyani, Maula E.
Wibawa, Teguh H. A.
Febrian, Muhamad B.
Setiadi, Yanuar
Widyasari, Eva M.
Daruwati, Isti
Kusumaningrum, Crhisterra E.
Subroto, Toto
author_facet Wongso, Hendris
Mahendra, Isa
Arnafia, Wyanda
Idar, Idar
Yusuf, Muhammad
Achmad, Arifudin
Holik, Holis A.
Kurniawan, Ahmad
Halimah, Iim
Sriyani, Maula E.
Wibawa, Teguh H. A.
Febrian, Muhamad B.
Setiadi, Yanuar
Widyasari, Eva M.
Daruwati, Isti
Kusumaningrum, Crhisterra E.
Subroto, Toto
author_sort Wongso, Hendris
collection PubMed
description The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19.
format Online
Article
Text
id pubmed-8778912
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87789122022-01-22 Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19 Wongso, Hendris Mahendra, Isa Arnafia, Wyanda Idar, Idar Yusuf, Muhammad Achmad, Arifudin Holik, Holis A. Kurniawan, Ahmad Halimah, Iim Sriyani, Maula E. Wibawa, Teguh H. A. Febrian, Muhamad B. Setiadi, Yanuar Widyasari, Eva M. Daruwati, Isti Kusumaningrum, Crhisterra E. Subroto, Toto Vaccines (Basel) Article The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19. MDPI 2022-01-17 /pmc/articles/PMC8778912/ /pubmed/35062789 http://dx.doi.org/10.3390/vaccines10010128 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wongso, Hendris
Mahendra, Isa
Arnafia, Wyanda
Idar, Idar
Yusuf, Muhammad
Achmad, Arifudin
Holik, Holis A.
Kurniawan, Ahmad
Halimah, Iim
Sriyani, Maula E.
Wibawa, Teguh H. A.
Febrian, Muhamad B.
Setiadi, Yanuar
Widyasari, Eva M.
Daruwati, Isti
Kusumaningrum, Crhisterra E.
Subroto, Toto
Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19
title Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19
title_full Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19
title_fullStr Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19
title_full_unstemmed Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19
title_short Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19
title_sort preclinical evaluation of chicken egg yolk antibody (igy) anti-rbd spike sars-cov-2—a candidate for passive immunization against covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778912/
https://www.ncbi.nlm.nih.gov/pubmed/35062789
http://dx.doi.org/10.3390/vaccines10010128
work_keys_str_mv AT wongsohendris preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT mahendraisa preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT arnafiawyanda preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT idaridar preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT yusufmuhammad preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT achmadarifudin preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT holikholisa preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT kurniawanahmad preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT halimahiim preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT sriyanimaulae preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT wibawateguhha preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT febrianmuhamadb preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT setiadiyanuar preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT widyasarievam preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT daruwatiisti preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT kusumaningrumcrhisterrae preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19
AT subrotototo preclinicalevaluationofchickeneggyolkantibodyigyantirbdspikesarscov2acandidateforpassiveimmunizationagainstcovid19